COMPANY

Lixte Biotechnology

HQ: Boca Raton, FL source · lixte.com ↗ · Southeast

Keywords: oncology cancer solid tumors Myelodysplastic Syndromes LB-100

Location: Boca Raton, FL · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Dec 23, 2025 Partnership Partnership / licensing announced Dec 23, 2025. Source: SEC filing. source ↗
Jul 8, 2025 Raise Follow-on offering — Registered direct: $1.5M (total, as published), announced Jul 8, 2025. Source: SEC filing. source ↗
2019-04 Trial start Phase 1/Phase 2: A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) source ↗
2013-02 Trial start I: Phase I Study of LB-100 With Docetaxel in Solid Tumors source ↗

Raised: $1.5M. Last 2 years.

Jul 8, 2025 Follow-on offering — Registered direct: $1.5M (total, as published), announced Jul 8, 2025. Source: SEC filing. source ↗
Dec 23, 2025 Partnership / licensing announced Dec 23, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03886662	A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)	Phase 1/Phase 2	Recruiting	2019-04	2021-05 (estimated)
NCT01837667	Phase I Study of LB-100 With Docetaxel in Solid Tumors	I	Completed	2013-02	2016-09 (actual)